Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Adult
Azithromycin
/ administration & dosage
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Drug Therapy, Combination
Female
Humans
Hydroxychloroquine
/ administration & dosage
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ drug therapy
Polymerase Chain Reaction
SARS-CoV-2
Viral Load
COVID-19 Drug Treatment
2019-nCoV
Azithromycin
COVID-19
Clinical trial
Hydroxychloroquine
SARS-CoV-2
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
16
03
2020
revised:
17
03
2020
accepted:
17
03
2020
pubmed:
25
3
2020
medline:
5
8
2020
entrez:
25
3
2020
Statut:
ppublish
Résumé
Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads. French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16 Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported in the litterature for untreated patients. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Despite its small sample size, our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Sections du résumé
BACKGROUND
BACKGROUND
Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads.
PATIENTS AND METHODS
METHODS
French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16
RESULTS
RESULTS
Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported in the litterature for untreated patients. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.
CONCLUSION
CONCLUSIONS
Despite its small sample size, our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Identifiants
pubmed: 32205204
pii: S0924-8579(20)30099-6
doi: 10.1016/j.ijantimicag.2020.105949
pmc: PMC7102549
pii:
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105949Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Références
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Travel Med Infect Dis. 2020 Mar 20;:101632
pubmed: 32205269
Clin Infect Dis. 2020 Mar 09;:
pubmed: 32150618
JAMA. 2020 Feb 24;:
pubmed: 32091533
Arch Intern Med. 1999 Jan 25;159(2):167-73
pubmed: 9927100
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Aug 15;1060:166-172
pubmed: 28622620
JAMA. 2015 Nov 17;314(19):2034-2044
pubmed: 26575060
Curr Opin Infect Dis. 2018 Dec;31(6):463-470
pubmed: 30299363
J Med Chem. 2006 May 4;49(9):2845-9
pubmed: 16640347
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188
pubmed: 32164085
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14408-14413
pubmed: 27911847
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
ACS Infect Dis. 2015 Jul 10;1(7):317-26
pubmed: 27622822
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Ophthalmology. 2016 Jun;123(6):1386-94
pubmed: 26992838
Int J Antimicrob Agents. 2020 Mar;55(3):105923
pubmed: 32070753